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ABSTRACT:
Kinesin motor proteins exert essential cellular functions in all eukaryotes. 
They control mitosis, migration and intracellular transport through interaction 
with microtubules. Small molecule inhibitors of the mitotic kinesin KiF11/Eg5 are a 
promising new class of anti-neoplastic agents currently evaluated in clinical cancer 
trials for solid tumors and hematological malignancies. Here we report induction of 
Eg5 and four other mitotic kinesins including KIF20A/Mklp2 upon stimulation of in 
vivo angiogenesis with vascular endothelial growth factor-A (VEGF-A). Expression 
analyses indicate up-regulation of several kinesin-encoding genes predominantly 
in lymphoblasts and endothelial cells. Chemical blockade of Eg5 inhibits endothelial 
cell proliferation and migration in vitro. Mitosis-independent vascular outgrowth 
in aortic ring cultures is strongly impaired after Eg5 or Mklp2 protein inhibition. 
In vivo, interfering with KIF11/Eg5 function causes developmental and vascular 
defects in zebrafish and chick embryos and potent inhibition of tumor angiogenesis 
in experimental tumor models. Besides blocking tumor cell proliferation, impairing 
endothelial function is a novel mechanism of action of kinesin inhibitors.  
INTRODUCTION
The ability of solid tumors to attract blood vessels 
(tumor angiogenesis) is one of the rate-limiting steps 
for tumor progression [1]. Vascular endothelial growth 
factor (VEGF-A) is a key hypoxia-induced angiogenic 
protein secreted by tumor cells acting on the endothelium 
to induce and sustain new blood vessel growth [2]. 
Neutralizing VEGF-A with drugs such as the humanized 
anti-VEGF-A antibody bevacizumab (Avastin) potently 
blocks tumor growth in numerous animal models. 
Associated with standard chemotherapy, bevacizumab is 
used worldwide against multiple cancer types and allows 
prolonged or progression-free survival. However, by far 
not all patients respond to anti-VEGF therapy and severe 
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side effects such as hypertension and proteinuria have 
been reported, a fact which has led to the retirement of 
bevacizumab as a treatment for metastatic breast cancer 
[3]. It is therefore a challenge to explore the molecular 
networks that regulate blood vessel growth to identify 
novel druggable targets. 
To discover novel downstream effectors of VEGF-A 
activity in the endothelium in vivo, we monitored global 
gene expression changes after application of recombinant 
human VEGF-A on the differentiated day-13 chick 
chorio-allantoic membrane (CAM) [4]. Numerous known 
genes associated with angiogenesis were up regulated 
by VEGF-A. Among the new ones, KIF4A, KIF11/Eg5, 
KIF15, KIF20A/Mklp2 and KIF23, all genes encoding 
mitotic kinesins, were consistently up regulated. 
Kinesins make up a family of about 45 proteins 
in humans; at least 12 of them are implicated in mitosis 
[5]. KIF11 encodes the Eg5 protein, which is essential 
for cell division [6]. Murine Knsl1 (KIF11) null-embryos 
die prior to implantation between morula and blastocyst 
stage [7, 8]. KIF20A/Mklp2 exerts important functions 
during mitosis by ensuring cleavage furrow formation and 
cytokinesis [9]. 
First evidence that kinesin inhibition might be 
explored as a new anti-cancer strategy came in 2004 [10] 
and chemical inhibitors of Eg5 have been designed and 
tested with success against solid tumors in preclinical 
tumor models [11]. Consequently, there are increasing 
numbers of clinical trials investigating the efficacy of Eg5 
inhibitors alone or associated with classical chemotherapy 
in hematological and solid malignancies [12]. There is 
a general consent that inhibitors of the mitotic kinesins, 
especially Eg5, have the potential to overcome side-effects 
associated with classical microtubule targeting agents 
such as Taxol, which include neutropenia, hair loss and 
peripheral neuropathy as well as resistance, thereby often 
limiting their usability [5, 13].
Mitotic kinesins have been studied in the context 
of cell division almost exclusively in tumor cells [12]. 
Beside their role in mitosis, an increasing number of 
reports point to the possibility that they may exert other 
biological functions. KIF11/Eg5 plays an important 
role in normal and cancer cell migration [14, 15]. Only 
recently, an important role of Eg5 in protein translation 
has been discovered [16] and KIF4A has been shown to 
be implicated in neuronal survival [17]. Since KIF11/
Eg5 and KIF20A/Mklp2 are promising drug targets, 
we sought to investigate the impact of their respective 
inhibitors on angiogenesis, a process that is central to 
tumor progression. 
RESULTS 
VEGF-A-induced gene expression in vivo
Human recombinant VEGF-A induces growth of 
new capillaries inside the CAM within 24h (Fig. 1b, c). 
Chicken microarray analysis of angiogenic areas of three 
Figure 1: Affymetrix GeneChip screening for VEGF-A-induced genes during CAM vascularization. Solvent or human 
recombinant VEGF-A was deposited on the differentiated CAM at day 13 of development. (a, b, c) 24h later, tissue with visible newly 
formed capillaries (asterisk in c) was isolated and further processed for mRNA isolation (n=3 CAMs per group). Control CAMs (a) did 
not show any vascular alterations (arrow: border of the carrier plastic disc). (d) To verify reproducibility of these experiments, fold-
change values of genes regulated in VEGF-treated CAMs were plotted against each other for correlation analysis. Significant correlations 
(Spearmans r ranging from 0.7 to 0.78, P<0.0001) were found for all comparisons indicating that VEGF effects on the CAM were consistent. 
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Table 1: Vascular gene expression program induced by VEGF-A.








KIF11 kinesin family member 11 23.22 0.10 --
CENPL centromere protein L isoform 2 4.56 0.29 --
TEK TEK tyrosine kinase, endothelial precursor 4.39 0.01 --
CENPE centromere protein E 4.05 0.29 --
ECSM2 hypothetical protein LOC641700 3.45 0.00 --
CD34 CD34 antigen isoform a 2.96 0.00 --
CLDN5 claudin 5 2.88 0.29 --
DPY19L1 dpy-19-like 1 2.65 0.02 --
MYCT1 myc target 1 2.59 0.00 --
ZNF521 zinc finger protein 521 2.59 0.00 --
CDH5 cadherin 5, type 2 preproprotein 2.54 0.00 --
SOX18 SRY-box 18 2.48 0.29 --
C13orf3 hypothetical protein LOC221150 2.28 0.29 --
SOX17 SRY-box 17 2.28 0.10 --
LMO2 LIM domain only 2 2.20 0.29 --
LIFR leukemia inhibitory factor receptor precursor 2.08 0.00 --
PECAM1 platelet/endothelial cell adhesion molecule (CD31 antigen) 2.86 0.00 171.25
SEC14L1 SEC14 (S. cerevisiae)-like 1 isoform a 2.60 0.00 61.47
TIE1 tyrosine kinase with immunoglobulin-like and EGF-like domains 1 4.20 0.00 35.13
PDGFB platelet-derived growth factor beta isoform 1, preproprotein 2.21 0.01 21.96
PRCP prolylcarboxypeptidase isoform 1 preproprotein 6.37 0.00 17.56
RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 2.97 0.04 17.56
PODXL podocalyxin-like isoform 2 precursor 2.27 0.00 13.17
NRP1 neuropilin 1 isoform a 2.42 0.00 12.55
MYO1C myosin IC isoform c 3.25 0.00 11.86
ELK3 ELK3 protein 2.07 0.01 10.25
LAMA4 laminin, alpha 4 isoform 1 precursor 2.68 0.00 9.27
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) 3.19 0.29 8.78
CDH13 cadherin 13 preproprotein 2.41 0.10 8.78
IFNGR1 interferon gamma receptor 1 precursor 2.05 0.29 8.78
USP1 ubiquitin specific protease 1 3.29 0.26 6.59
SEC24C SEC24-related protein C 2.71 0.05 6.59
C14orf108 chromosome 14 open reading frame 108 2.20 0.05 6.59
SERPINH1 serine (or cysteine) proteinase inhibitor, clade H, member 1 precursor 2.24 0.00 6.23
KIAA1671 KIAA1671 protein 2.41 0.18 5.85
FLI1 Friend leukemia virus integration 1 2.75 0.32 4.39
MKI67 antigen identified by monoclonal antibody Ki-67 2.55 0.26 4.39
BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog 2.50 0.44 4.39
TM4SF18 transmembrane 4 L six family member 18 2.34 0.44 4.39
NUSAP1 nucleolar and spindle associated protein 1 isoform 2 3.06 0.12 3.84
KIF20A kinesin family member 20A 3.66 0.26 3.66
DOCK9 dedicator of cytokinesis 9 4.73 0.30 3.51
AKAP12 A-kinase anchor protein 12 isoform 2 2.62 0.25 3.29
RRM1 ribonucleoside-diphosphate reductase M1 chain 2.60 0.07 3.22
PDE4B phosphodiesterase 4B, cAMP-specific isoform 2 3.89 0.29 3.14
LMBR1 limb region 1 protein 2.43 0.29 3.14
PSMD1 proteasome 26S non-ATPase subunit 1 2.91 0.02 3.05
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individual CAMs was performed. 317 probes showed 
significantly increased expression (more than 2-fold in 
at least two out of three comparisons; Table S1). Fold-
changes of significantly regulated genes in VEGF-A-
stimulated CAMs replicates showed strong correlation 
(Spearman R ranging from 0.7 to 0.78, P<0.0001 in all 
comparisons: VEGF CAM 1 vs. VEGF CAM 2, VEGF 
CAM2 vs. VEGF CAM 3, VEGF CAM 1 vs. VEGF CAM 
3; Fig. 1d). 
An automated reciprocal blast search identified 
human orthologs of the 317 chick genes and an in silico 
prediction of endothelial vs. non-endothelial expression 
of these revealed those with expression enriched in 
endothelium [19, 25]. 206 human ortholog genes were 
identified and submitted to gene ontology (GO) using 
the DAVID interface (Table S2). Interestingly, GO 
terms associated with mitosis were highly significantly 
enriched (11.6-fold, FDR: 7.44x10-13). Another annotation 
cluster identified GO term “blood vessel development” 
(enrichment 5.5-fold, FDR 1.66x10-4). A total of 53 single 
genes with human orthologs and preferential endothelial 
expression (q-value >0.5) were identified (Table 1). This 
list contained numerous key angiogenic regulators with 
known endothelial expression indicating that relevant 
biological material was isolated for microarray analysis.
One of the genes with strong up-regulation and 
specific prediction of endothelial cell over-expression 
was KIF11 (coding for the Eg5 protein), a molecule that 
has not yet been studied in the context of angiogenesis. 
Up-regulation of a total of five kinesins by VEGF-A was 
confirmed by semi-quantitative qPCR and was 4.79 for 
KIF4A, 3.8 for KIF11, 6.25 for KIF15, 5.58 for KIF20A 
and 2.95 for KIF23 using HNRPH1 as normalizer 
because its expression did not differ between control and 
VEGF-treated CAMs (Supplemental Table S1, last line). 
Increased production of Eg5 protein was further confirmed 
in vitro, after stimulating HUVECs with VEGF165 
protein. Increase in Eg5 protein could be abolished by 
simultaneous application of the neutralizing anti-VEGF 
antibody Avastin (Fig. S1). 
Kinesin expression and localization 
We performed an in silico bioninformatic screen 
[25] on all genes encoding kinesins. Eight out of 38 
kinesin transcripts showed enrichment in the endothelial 
EST pool more than two-fold, including the VEGF-A-
induced kinesins KIF11, KIF15 and KIF20A (Table S3).
In freshly isolated human foreskin, Eg5 staining 
overlapped to a great extent with that of CD31, indicating 
that blood endothelial cells strongly express Eg5 protein 
(Fig. 2a). Lymphatic vessels identified by podoplanin 
immunoreactivity were also Eg5 positive (Fig. 2b). 
CLIC2 chloride intracellular channel 2 2.43 0.29 2.93
PRPF8 U5 snRNP-specific protein 2.10 0.07 2.85
NUP93 nucleoporin 93kDa 2.84 0.26 2.79
RBBP4 retinoblastoma binding protein 4 1.85 0.29 2.56
AMD1 S-adenosylmethionine decarboxylase 1 isoform 1 precursor 2.08 0.46 2.51
GOT2 aspartate aminotransferase 2 precursor 2.50 0.02 2.45
In silico endothelial-enriched ortholog genes (q-value <0.5) regulated more than 2-fold in at least 2 of 3 comparisons are shown (n=53). As expected, and 
consistent with active vascular network formation, numerous key angiogenic regulators were induced, such as TEK, CD34, SOX18, LMO2, PECAM1, 
NRP1, FLI1 and KDR (italicized). Also note induction of mitotic kinesins, KIF11 (encoding Eg5) and KIF20A (in bold). 317 probe sets with significant 
increase after VEGF-A stimulation in at least two out of three comparisons are shown in Supplemental Table S1.
Figure 2: Eg5/KIF11 expression studies in normal and 
cancerous tissues. (a, b) Sections of human foreskin were 
double-stained with anti-Eg5 and either anti-CD31 or anti-
podoplanin antibodies. CD31-positive blood capillaries were 
also positive for Eg5 (arrows). (b) Colocalisation of Eg5 and 
podoplanin was also observed in lymphatic vessels (arrows). 
(c) Immunohistological staining reveals also expression of Eg5 
in tumor blood vessels in three different glioblastoma patients 
(arrows). (d) Strong vascular expression for Eg5 is also found in 
renal cell carcinoma patients (arrows).
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Immunohistological analysis of human glioblastoma 
samples revealed staining of Eg5 in endothelial and tumor 
cells (Fig. 2c). In renal cell carcinoma, predominant 
staining was observed in capillaries (Fig. 2d). Mklp2/
KIF20A protein showed an even stronger expression in 
endothelial cells in several normal tissues (heart, placenta, 
endometrium, oral mucosa; Fig. S4a-d) and glioblastoma 
vessels (Fig. S4e, f). KIF20A transcripts were found 
mostly in ECs in glioblastoma (n=4 patients, arrows; Fig. 
S4h), matching the vascular localization of CD31 (Fig. 
S4g). All five VEGF-induced kinesins are over expressed 
in a large number of human malignancies as evidenced by 
Oncomine analysis (Fig. S2a). In small cell lung cancer, 
fibrosarcoma and glioblastoma, these kinesins are found 
up regulated, compared to normal tissue (Fig S2b-d). 
We further focused on KIF11 and KIF20A expression in 
glioblastoma and found general over-expression in this 
pathology in two additional studies (Fig S3, left graphs). 
When expression values were plotted individually per 
patient, a heterogeneous expression pattern was revealed 
with about one third of patients under- expressing KIF11 
and KIF20A, whereas two-thirds of patients over-express 
both genes (Fig S3, right graphs). 
To further shed light on the co-expression of the 
Figure 3: Chemical inhibition of Eg5 in normal and malignant cells. (a, b) Specific inhibition of Eg5 by dimethylenastron 
(DMN) leads to a dose-dependent blockade of cell proliferation in both, blood (HUVEC) and lymphatic endothelial cells (LEC). (c, d) 
Nearly complete inhibition is achieved in HUVECs and human brain endothelial cells (hCMEC/D3) after 72h at 1 µM (P<0.0001) in the 
presence of serum. (e) Eg5 inhibition blocks endothelial cell proliferation regardless the mitogen used for stimulation (FGF-2 or VEGF) in 
bovine aortic endothelial cells (BAE; P<0.005). (f-h) Human and murine glioma cell proliferation is inhibited with comparable efficacy. (i) 
Growth of five neuroblastoma cell lines is also significantly inhibited in the presence of 0.5 or 1 µM DMN.
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five kinesins, we performed co-expression analysis using 
KIF11 gene as bait (Fig. S5a). Expression was low in 
normal brain, but elevated in anaplastic oligodendroglioma 
(French_brain study1) and all five kinesins were highly 
1  Oncomine nomenclature to identify original studies. 
Detailed reference can be found at www.oncomine.org.
co-expressed (correlation from 0.903 for KIF4A to 0.872 
for KIF15; black arrows). Similar co-expression could be 
evidenced in a glioblastoma study (Freje_brain study; Fig. 
S5b). Co-expression could be linked to other pathological 
features such as the vascularization state of a tumor, as 
evidenced in the Wurmbach_liver study for hepatocellular 
Figure 4: Inhibition of Eg5 or KIF20A protein function impairs in vitro angiogenesis in the absence of mitosis. (a-d) 
HUVECs grown on matrigel received indicated treatments. They were photographed at 4x magnification after 14h and morphologically 
annotated by the WIMASIS platform (ISP = Ispinesib; DMN = dimethylenastron; PAP = paprotrain; a) left image: unprocessed raw data, 
right image: automated annotation by WIMASIS). (e-h) Morphological parameters characteristic of in vitro angiogenesis are significantly 
reduced by chemical inhibition of Eg5 or Mklp2 protein. 
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carcinoma: KIF11, KIF4A and KIF15 were strongly co-
expressed with KIF20A (>0.8; Fig. S6) and expression 
levels increased with the degree of vascularization 
and were highest in tumors with macroscopic vascular 
invasion.
We also used data provided by the BioGPS project 
[26] to compare KIF11 and KIF20A expression in 84 
human tissues and cell lines. Only 8 cell lines had relative 
KIF11 mRNA levels higher than 20 (Fig. S7), highest 
levels were found in 721_B_lymphoblasts (274.8), 
followed by other lymphoblastic lines and CD105+ and 
CD34+ endothelial cells (167.95 and 64.75). Highly 
comparable data were found for KIF20A, relative 
expression values of KIF11 and KIF20A were highly 
correlated (Spearman r=0.8492, P<0.0001). These 
expression data point to a potential role of kinesins in the 
angiogenic process.
Eg5 blockade inhibits proliferation of endothelial 
cells and tumor cell lines
Growth of HUVECs and LECs was inhibited by 
dimethylenastron (DMN) in a dose- and time-dependent 
manner (Fig. 3a-c). Inhibition became evident after 72h of 
treatment with first effects at 0.5 µM and maximal effects 
at 1 µM. Significant growth inhibition at doses from 0.5 
to 1 µM was also observed in the brain microcapillary 
endothelial cell line hCMEC/D3 (Fig. 3d), and bovine 
aortic endothelial cells (BAE) stimulated with VEGF-A 
or FGF-2 in reduced growth medium (Fig. 3e). Eg5 
blockade at 1 µM led to complete growth inhibition after 
72h, regardless of the type of mitogen used (Fig. 3i). 
Similar inhibition was observed in the human malignant 
glioma cell lines U87 and T98G (Fig. 3f, g), the murine 
glioma cell lines GL261 (Fig. 3h), and five different 
neuroblastoma cell lines (Fig. 3i).
KIF11/Eg5 and KIF20A/Mklp2 inhibition 
interferes with in vitro angiogenesis in the absence 
of mitosis
Strong perturbation of in vitro angiogenesis was 
observed after Eg5 blockade using two specific inhibitors, 
dimethylenastron (DMN; Fig. 4b) and ispinesib (ISP; Fig. 
4c and Video 1), whereas solvent-treated cultures were not 
affected (Fig. 4a and Video 2). Inhibition was observed 
with ispinesib at both doses (5 and 10 µM). Number of 
vascular chords was reduced by 2-fold, branching points 
by nearly 90%, independent chords increased 3-times and 
number of loops was reduced by 90% (Fig. 4e-h). Less 
potent inhibition was observed with the Eg5 inhibitor 
DMN (Fig. 4e-h). Chemical blockade of Mklp2/KIF20A 
protein using paprotrain also inhibited chord formation 
(Fig. 4d), albeit at higher doses (20 µM) and to a lesser 
extent than the KIF11/Eg5 inhibitors (Fig. 4e-h). Mitosis 
is a very rare event in our assay conditions (Fig. S8). 
These results demonstrate that kinesin inhibition affects 
biological processes relevant for angiogenesis, which are 
distinct from mitosis.
Kinesin inhibition affects endothelial cell 
adhesion, spreading and migration
Vascular chord formation requires cell adhesion 
and migration. Eg5 function is required for proper cell 
adhesion of HUVECs plated on different matrix proteins. 
Ispinesib-treated cells (5 µM) adhered poorly and 
detached after washing prior to Coomassie staining (Fig. 
S9a). Cells appeared more rounded and phalloidin staining 
revealed an altered organization of the actin cytoskeleton, 
with an appearance of cortical actin and strong reduction 
of stress fibers (Fig. S9b). Quantification of the number 
of spreading cells revealed a significant decrease after 
Eg5 blockade using ispinesib (P<0.0001, Fig. S9c). 
Endothelial cell migration was measured over an 18h 
time period. Migrating HUVECs in serum and DMSO 
control wounds covered around 90% of the denuded area 
(Fig. S10a, b), whereas Ispinesib-treated cultures were 
covered by 36% and paprotrain cultures only by 28% 
(P<0.0001; Fig S10c). A comparable result was obtained 
in a second series of experiments after siRNA-mediated 
knock-down of KIF11 in HUVECs. Wound closure after 
20h of migration was reduced by 31% compared to control 
cultures (P=0.0007; Fig. S10d).
Vascular outgrowth in the mouse aortic ring assay 
is inhibited by kinesin blockade
We next tested effects of Eg5 and Mklp2 inhibition 
in an ex vivo angiogenesis model where spontaneous 
vascular growth occurs after incubation of aortic rings 
in matrigel [27]. After 8 days of treatment, vascular 
outgrowth around rings was significantly inhibited at 
ispinesib doses as low as 50nM (P<0.0001; Fig S11a, b), 
whereas paprotrain-mediated inhibition was effective only 
around 20µM (P<0.001; Fig. S11a, c).
kif11/Eg5 is required for CAM development and 
physiological hematopoiesis and angiogenesis in 
zebrafish
DMN injection into the allantoic vesicle at 
Hamburger&Hamilton stage 21 (HH21) embryos 
completely inhibited expansion of the vesicle (HH24; Fig 
5b, c). Only a rudimentary tissue mass with a primitive 
vascular network developed. This effect was consistent 
in all DMN-injected embryos, control embryos showed 
normal growth of the allantoic vesicle (arrows, Fig. 5a). 
In normal zebrafish embryos, embryonic lethality 
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was only observed in the ISP treatment groups, ranging 
from 8% at 0.1 µM, up to 18% at 1 µM. Analysis of 
live embryos revealed changes in the morphology of 
the posterior blood islands (PBI) as well as a reduction 
of circulating blood cells (Fig. 5d). This phenotype did 
not occur in control embryos, but up to 15% of embryos 
displayed these modifications at 1 µM (P=0.0067) and 
3 µM ISP (P=0.0041), suggesting that the developing 
hematopoietic system is sensitive to Eg5 inhibition. 
We therefore examined expression of kif11 in 
24hpf embryos; a time point where a transient wave of 
hematopoiesis takes place in the PBI and circulation 
begins [28]. A fli1 probe visualized cellular components 
of the developing blood vascular system, including the 
PBI. The kif11 probe labeled various cellular components 
of the embryo with different intensities; strong staining 
Figure 5: Effects of kinesin blockade in chick and zebrafish embryos. (a) Control chick embryos showed normal expansion of 
the allantoic vesicle (al) at day 4.5 (HH24). Arrows point to the border of the vesicle. (b, c) Eg5 inhibition leads to complete arrest of CAM 
development; only a rudimentary tissue with a primitive vascular network develops. (d) Blockade of Eg5 function using ispinesib (ISP) 
from 24 to 48 hpf leads to a significant increase of embryos with modification of the posterior blood islands (PBI) or reduction of blood 
cells at 1 and 3µM. (e) Phenotype-score of Tg(kdrl:EGFP)s843 embryos injected with indicated morpholinos (Mo) at 48 hpf. At doses higher 
than 0.5 ng, most embryos die and show severe edema and circulation defects. (e, f) At 0.2 ng, 46% of embryos displayed a mild phenotype 
with a curved and shortened tail and normal circulation, 34% had severe circulation defects, including pericardial edema (arrow), and 8% 
of embryos were dead (70x magnification). (g) Fluorescence micrographs of control and kif11 morphants (115x magnification). Asterisk 
and arrows denote random vascular defects. DLAV = dorsal longitudinal anastomotic vessel, ISV = intersomitic vessels. 
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Figure 6: Eg5 inhibition reduces tumor angiogenesis in experimental tumor models. (a-d) U87-derived gliomas on the 
CAM were treated with indicated doses of Eg5 inhibitors. Biomicroscopy images were taken at day 4 of tumor development. Note visible 
induction of necrosis (arrows in b-d) at the tumor surface after Eg5 inhibition. (e-f) Immunohistological examination of experimental 
glioma. A dense vascular network occurred in control tumors, whereas Eg5 inhibition leads to reduced tumor angiogenesis underneath 
the tumor surface (asterisk), denoted by the dashed line (f), especially at two treatments of DMN (g) or ISP (h) per day. (i) A significantly 
higher number of poorly vascularized tumors (+) was within the ISP-treated group, whereas few tumors treated with ISP appeared highly 
vascularized (+++). (j) Ispinesib also reduced tumor size (representative tumors are shown); (k) weight (P= 0.0037) and (i) vascular density 
(P=0.0184) in an orthotopic renal cell carcinoma model. (j). Short-term treatment (48h) with ispinesib lead to a significant increase of 
dilated capillaries (P=0.0284; n, p) whereas overall vascular density remained unchanged (NS; o).
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was evident in the PBI and PCV (posterior cardinal vein), 
where a partial co-localisation with the fli1 signal was 
observed (Fig. S12a). 
Morpholino-mediated knock down of the kif11 
gene in the transgenic Tg(kdrl:EGFP)s843 line had severe 
effects on embryonic morphology and survival (Fig. 
5e). Whereas almost all control morpholino embryos 
developed normally, the number of dead and affected 
embryos increased even at a morpholino dose of 0.2 ng 
(P<0.005; 0.2 ng vs. controls). At 0.5 ng, effects were even 
more severe and 70% of embryos were dead. At the lower 
dose, embryos appeared curved and severe phenotypes had 
pericardial edema (Fig. 5f, arrow). Various morphological 
defects occurred in the developing vasculature, ranging 
from shortened inter-somitic vessel (ISV) sprouts (Fig. 5g; 
first two arrows), discontinuity of the dorsal longitudinal 
anastomotic vessel (DLAV) (asterisk, mild phenotype) 
and branching defects (third arrow). Embryos with 
severe phenotypes had complete absence of the DLAV 
and shortened and distorted ISV sprouts (arrows; more 
examples are shown in Fig. S12b).
These results – together with the high expression 
levels of KIF11 in hematopoietic and endothelial cells – 
suggest that Eg5/KIF11 might be a novel target for anti-
angiogenic therapy in pathological settings.
Interfering with KIF11/Eg5 function reduces 
tumor angiogenesis
Experimental gliomas grown on the chicken CAM 
are accessible to topical treatment with chemical tyrosine 
kinase inhibitors such as imatinib mesylate or PTK787 
[23]. During the three-day anti-Eg5 treatment period, 
no measurable tumor size reduction occurred. However, 
biomicroscopic observation of the tumors at day 4 showed 
increasing whitish areas at the tumor surface (Fig. 6a-
d). These areas contain necrotic cells, as confirmed by 
subsequent histology (Fig. 6f-h). Immunohistological 
analysis of the tumors showed reduced numbers of 
angiogenic capillaries after treatment with a single dose 
of DMN per day (Fig. 6f). This effect was much stronger 
after two DMN doses; the tumors were almost completely 
devoid of blood vessels, whereas tumor cells apart from 
the necrotic areas appeared normal (Fig. 6g). Tumor cell 
morphology evidenced by vimentin staining was not 
altered by DMN treatment, even at the highest doses. Two 
treatments of ispinesib caused widespread destruction 
of cellular components of the tumor as evidenced by 
non-specific staining of dead cells for sambucus nigra 
agglutinin (SNA lectin), clearly visible below the surface 
(Fig. 6h). A significantly higher number of ispinesib-
treated tumors were found in the poorly vascularized 
group (P<0.005) and accordingly, only a small number 
of ispinesib-treated tumors were classified in the highly 
vascularized group (P<0.005; Fig 6i).
In a murine tumor model, RENCA cells implanted 
orthotopically in kidneys give rise to highly aggressive and 
fast growing tumors with tumor weights of up to 4 g after 
a 3-weeks period (median 1.9 g; Fig. 6j, k). Twice-weekly 
treatment with ispinesib potently reduces tumor weight 
(median 708 mg; P=0.0037) and tumor angiogenesis 
(P=0.0184; Fig. 6l, m).
When established tumors were treated for 48h 
with ispinesib, no growth reduction or effect on vessel 
density was observed (Fig. 6n, o). However, tumor 
vessel in treated animals appeared more dilated and had 
a significantly higher number of dilated vessels (Fig 6p; 
P=0.0284).
DISCUSSION
It is widely accepted that the secreted growth 
factor VEGF-A and its transmembrane receptors, are key 
regulators of embryonic and pathologic angiogenesis 
[2]. The angiogenic switch is a key event during tumor 
progression [1] and there has been much hope that anti-
VEGF-A therapies may inhibit tumor growth significantly. 
In practice, anti-VEGF strategies have their limitations, 
due to a limited number of therapy responders, severe 
side effects of the VEGF-targeting antibody Avastin and 
raising concerns about the high costs of such treatment 
[3]. However, VEGF-A is a major proangiogenic factor in 
vivo, and therefore, it is of crucial importance to identify 
new druggable targets, which are associated with its 
downstream functions.
We chose the chick embryonic day-13 chorio-
allantoic membrane (CAM), since human VEGF-A 
specifically induces angiogenesis in this tissue [4]. A 
global analysis of regulated angiogenesis genes in vivo 
is more reliable than in vitro transcriptome analysis of 
angiogenic endothelial cells, since major molecular 
differences have been found when endothelial cells are 
studied separated from their normal tissue context [29, 
30].
Numerous genes up-regulated by VEGF-A have 
not yet been studied in the context of angiogenesis such 
as members of the kinesin family of motor proteins. 
We investigated the effects of kinesin inhibition on the 
angiogenic process in vitro and in vivo, focusing on Eg5/
KIF11 and Mklp2/KIF20A.
Our bioinformatics analysis and immunostaining 
results of normal human foreskin (Fig. 2) show that KIF11/
Eg5 is strongly expressed in blood and lymphatic vascular 
ECs. Human foreskin ECs also express VEGFR-2, a 
marker of angiogenic capillaries [31]. Only cells from the 
hematopoietic lineage (normal or neoplastic), together 
with CD34+ and CD105+ endothelial cells also displayed 
high levels of KIF11 and KIF20A kinesins (Fig. S7). 
An observation in line with these results is the strong 
expression of kif11 in the posterior blood islands of 
zebrafish embryos. In addition, inhibition of Eg5 function 
Oncotarget11www.impactjournals.com/oncotarget
by ispinesib in this model leads to modification of this 
structure or reduced number of blood cells. In humans, 
neutropenia is a frequent side effect of anti-kinesin therapy 
[32], suggesting that Eg5 function is also required for 
generation and maintenance of immune cells.
Morpholino-mediated knock-down of kif11 results 
in vascular pattern defects in the trunk vasculature (Figure 
5 e-g, Fig. S12b). These results point to an important 
function of KIF11/Eg5 in the endothelial cell lineage. 
Besides endothelial cell proliferation, other 
biological processes such as chord formation also require 
Eg5 and Mklp2. Recent insight from genetic studies 
further support the notion that KIF11 is required for 
development of normal retinal and lymphatic vessels, 
since KIF11 mutations cause autosomal-dominant 
microcephaly associated with lymphedema and/or 
chorioretinopathy [33].
Cell adhesion, spreading and migration that 
are critical for vascular chord formation are strongly 
perturbed by Eg5 and Mklp2 inhibition (Figs. S9, S10). 
We observed a modification of the cytoskeleton in cells 
treated with ispinesib, with an increase of cortical actin 
and strong reduction of stress fibers. These changes 
in the cytoskeleton are most likely responsible for the 
reduced migratory and adhesive capacity after Eg5 
inhibition. Just recently, it has been shown that Eg5 also 
has a function in normal and malignant cell migration 
[14, 15]. There is evidence from the literature that DMN 
is highly specific for Eg5 kinesin, it binds to a region of 
the protein composed of loop 5, helix α2 and α3, which 
is not conserved in other kinesins [34, 35]. ISP, the 
second inhibitor we used ISP has been shown to be more 
than 70.000-times more selective for Eg5 than for other 
kinesins [36]. Further, siRNA-mediated knockdown of 
the KIF11 gene reduced cell migration comparable to 
chemical inhibition. 
Interestingly, all five kinesins induced by VEGF-A 
are also present in the highly significant 67-gene signature 
termed CINSARC (complexity index in sarcomas), 
which is associated with poor clinical outcome in several 
cancer types [37]. It is tempting to speculate that VEGF-
A-induced kinesins contributes to bad prognosis in 
human cancers or reflects the state of an activated tumor 
endothelium. Significant co-expression of these five 
kinesins has also been evidenced by bioinformatic analysis 
in various malignant tumors, especially in brain tumors 
(Fig. S5). In hepatocellular carcinoma (HCC), increasing 
kinesin (co-) expression is furthermore associated with the 
vascular status of the tumors (Fig. S6). Another group has 
just recently confirmed overexpression of KIF20A in HCC 
[38].
As expected, Eg5 inhibition stops glioblastoma 
cell growth [39]. Eg5 inhibitors not only block 
proliferation of adult tumor cell lines, but also those 
derived from childhood tumors. In the progressed stage 4 
neuroblastoma, the 5-year survival rate is only 20 – 30% 
[40] and high vascular density is characteristic for the 
progressed neuroblastomas [41]. Further studies should 
investigate the efficacy of anti-kinesin treatment in this 
kind of malignancy.
In the light of our in vitro results on Eg5/KIF11 
inhibition of endothelial cells, it can be expected that 
Eg5 inhibition might have a dual effect as it affects both 
malignant cells and tumor vasculature. Inhibition of tumor 
angiogenesis in the short-term experimental glioma model 
[23] was the predominant effect observed, suggesting that 
the endothelium constitutes an important target for this 
inhibitor.
Oncomine expression data show that KIF11 
transcripts are not overexpressed in kidney cancer, 
however, we have found Eg5 protein expression in 
capillaries of RCC and just recently, Eg5 immunoreactivity 
has been evidenced in a large study using 164 patient 
RCC tumors, with higher expression predicting poor 
disease outcome [42]. Eg5 inhibition significantly reduces 
experimental kidney cancer growth and angiogenesis. 
Short-term anti-Eg5 treatment did not alter tumor vessel 
density or led to regression of vessels, but changed 
vascular morphology. Tumor capillaries were significantly 
more dilated in the treatment group, suggesting a 
vascular remodelisation effect of ispinesib.  Even though 
classical anti-VEGF agents generally causes vascular 
“normalization” including reduction of vessel diameter 
[43], dilatation of tumor capillaries after different anti-
angiogenic treatments has recently described in animal 
models as well in human tumors [44, 45]. Different 
treatment durations and drug combinations may account 
for these differences; however, our results show that the 
tumor vasculature is affected by Eg5 inhibition.
This may open up new therapeutic perspectives such 
as targeting kinesin inhibitors to the tumor endothelium 
and stroma [46] to enhance the therapeutic efficacy.
Furthermore, combination of small-molecule Eg5 
inhibitors with anti-angiogenic agents may reduce side 
effects or increase the number of responders to anti-
angiogenesis treatment. Eg5 blockade not only inhibits 
VEGF-A-induced cell proliferation, but also FGF-2 
stimulated proliferation and thus has a more broad-
range effect than specific VEGF inhibitors (Fig. 3e). 
It is therefore tempting to speculate that Eg5 inhibition 
might render endothelial cells refractory to growth stimuli 
secreted by tumor cells, thereby maintaining a potent anti-
angiogenic environment. 
Even though single anti-angiogenic treatment 
works well in animal models, combination with standard 
chemotherapy is needed for most tumor types to obtain 
results in patients. A special emphasis should be given 
to the fact that cells from the hematopoietic lineage 
overexpress Eg5 (and Mklp2). Patients suffering from 
these highly proliferative malignancies might benefit 
from kinesin inhibition due to its dual anti-proliferative 
and anti-angiogenic effect. Since a frequent side effect 
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of Eg5 inhibitors is neutropenia, efforts should be made 
to develop specific cell and tumor targeting kinesin-
inhibition strategies to enhance their efficacy.
Evidence is emerging that over expression of KIF4A 
and KIF18A may play roles in tumor progression [47, 48]. 
Furthermore, knock-down of the KIF23 gene has been 
shown to abrogate glioma cell proliferation and tumor 
growth in vivo [49]. This opens the perspective that other 
kinesins may serve as druggable targets for anti-cancer 
therapy.
Taken together, our results provide evidence that 
kinesins, which lay downstream of angiogenic growth 
factors signaling, mediate essential processes important 
for physiological and pathological vascular growth and 
may constitute a potential therapeutic target for anti-
vascular tumor therapy. 
MATERIAL AND METHODS
Detailed protocols are in the supplemental data 
section.
Identification of genes regulated by VEGF-A on 
the CAM
Chick embryos were handled as described [18]. 
RNA was extracted from three CAMs treated each with 
3µg of recombinant human VEGF-A and compared 
individually to pooled equivalent quantities of RNA from 
three normal CAMs. Affymetrix chicken microarrays were 
processed as published [19]. Bioinformatic analyses of 
kinesin expression are detailed in the supplemental data 
section.
Semi-quantitative PCR
To verify microarray data, semi-quantitative PCR 
was performed on the same material used for microarray 
hybridization using efficient primers against VEGFR1, 
VEGFR2, KIF4A, KIF11, KIF15, KIF20A and KIF23, 
normalized to HNRPH1, which shows no changes during 
normal CAM development [19] and which is not induced 
by VEGF (Supplemental Table S1, last line). 
Chemical inhibitors
Indirubin-3’-monoxime (IRO, CDK/GSK-
3β inhibitor) [20] was purchased from Sigma, 
dimethylenastron (DMN, Eg5 inhibitor) was from Sigma 
or Chemstep Molexplorer (Martillac, France), ispinesib 
mesylate (ISP, Eg5 inhibitor) was from Selleck Chemicals 
(Houston, Tx, USA). (Z)-2-(1H-indol-3-yl)-3-(pyridin-
3-yl)acrylonitrile (paprotrain = PAssenger PROteins 
TRAnsport INhibitor, MKLP2 inhibitor) [21] was 
synthesized by Chemstep Molexplorer. 
Cell culture and proliferation assays
Vascular endothelial cells (HUVECs, BAEs, 
hCMEC/D3 and tumor cell lines (U87, T98G, GL261, 
CHP134, GIMEN, Kelly, IMR5 and SHEP) were cultured 
using routine cell culture conditions. 
Endothelial cell adhesion, spreading, migration 
and tubulogenesis assays
These assays were performed with HUVECs using 
standard protocols (see supplemental methods).
Mouse aortic ring assays
Vascular outgrowth in this assay was evaluated 
using freshly isolated mouse aortic ring fragments (for 
details see supplemental methods).
Chemical inhibition of Eg5 in chick embryos
Chick embryos were injected with 3 µl of 
dimethylenastron (1 µg/µl) at Hamburger & Hamilton 
(HH) stage 21 (3.5 days) into the allantoic vesicle (n=20 
embryos). Control embryos (n=15) received equal volume 
of solvent (DMSO). Embryos were examined under a 
biomicroscope the following day at stage HH24.
Zebrafish experiments
All zebrafish experiments were carried out 
using standard procedures (described in supplemental 
material and methods). In brief, Tg(kdrl:EGFP)
s843 embryos [22] were microinjected at the 1-2 
cell stage with 0.2-1 ng kif11 morpholino (MO) 
(CTGGTACTTGTGATGATGCCATGTT; 
Gene Tools, USA) or standard control MO 
(CCTCTTACCTCAGTTACAATTTATA; Gene Tools, 
USA). Higher kif11 MO doses were lethal and did not 
allow further analysis. At 48 hours post-fertilization (hpf), 
embryos were phenotype-scored and photographed. For 
chemical Eg5 inhibition, normal zebrafish embryos were 
treated with indicated doses of ispinesib at 24 hpf and 
phenotype-scored at 48 hpf.
Experimental tumor models
U87 glioma cells were implanted on the CAM as 
described [23] and treated once or twice daily with DMN 
or ISP, at indicated doses. Control tumors received solvent 
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(DMSO). Tumors were photographed in vivo and blind-
scored by seven investigators familiar with the model for 
degree of vascularization [24], and processed for histology. 
The orthotopic renal carcinoma model is detailed in the 
supplemental data section.
Histology, immunohistology and fluorescence in 
situ hybridization
Unfixed human foreskin from healthy donors was 
used for Eg5 (polyclonal rabbit anti-human, Abcam 
ab37009) co-localization studies with lymphatic (mouse-
anti-human podoplanin, ReliaTech, Germany) and 
vascular endothelium (mouse anti human CD31; BD 
clone WM59). For analysis of experimental glioma, anti-
vimentin (clone V9, Neomarkers) was used. Chick blood 
vessels were stained with sambucus nigra lectin (SNA, 
Vector Labs), and nuclei counterstained with DAPI. For 
in situ hybridization, fluorescent zebrafish probes kif11 
and fli1 were used on whole embryos. Human tumor 
sections were analyzed for Eg5 expression by standard 
immunohistochemistry (www.proteinatlas.org) and for 
KIF20A expression using QuantiViewRNA hybridization 
(Panomics-Affymetrix), details are in the supplemental 
methods section. 
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